Introduction
The evolution of clinical trials dates from the eighteenth century. 1 The quality of medicine affects not only the individual patient but also has a significant impact on socio-economical aspects and national health care. The consequences of not conducting appropriate clinical trials at the proper time can be serious and costly. Only recently after digitalis had been used for some 200 years, a large clinical trial evaluated the effect on mortality from congestive heart failure. 2 An example of higher paediatric relevance was the use of high concentrations of oxygen for the therapy in premature infants until a clinical trial demonstrated its harm. 3 Evidence-based medicine requires that every medical decision be based on the best evidence available. Clinical trials are, by far, the clearest method to determine medical evidence, but evidence is ranked according to several levels of quality 4 (Table 1) . To the dismay of many, the lowest level of evidence (level V) is the expert opinion, that is, the clinical experience of an acknowledged authority in the field or evidence based on physiology, bench research or 'first principles'. Non-experimental, well-designed comparative and descriptive trials, case-cohort or case-control trials reach level IV and III, respectively. Level I is achieved with controlled trials, and the crown jewels of evidence-based medicine (Level Ia) are systematic reviews of randomized controlled trials, a meta-analysis.
Why do we need clinical trials in children?
In 1998, Conroy et al. 5 conducted a study of the 'off-label' and 'off-licence' use of drugs in paediatrics. In their investigations, the scientists determined that 46% of the prescriptions that they recorded were for 'off-label' or 'offlicence' products and 67% of the minor patients included in the study had been given such products without proper evidence of dosage, tolerability and efficacy. These drugs had never been actually studied in this population in the European Union community (EU). This practice is a threat to the quality of medical care and the health of children as the risk of adverse effects increases significantly 6 ( Figure 1 ). Although in the ambulatory setting approximately 13% of all prescribed pharmaceuticals are off-label or unlicensed, the situation is most disturbing in neonatology, where approximately 90% of the drugs in use are unlicensed. 7 The dramatic improvement of the overall survival in children with oncological diseases through treatment optimization studies is a prime example for the tremendous need of properly conducted trials in paediatrics.
The need for evidence in paediatrics was long neglected by politicians and the pharmaceutical industry. Besides the public opinion and ethical considerations, the financial goals of the pharmaceutical industry are often the primary motive for the lack of clinical trials in children. The standard practice of reducing the dose for paediatric administration instead of conducting formal dose-ranging studies has been historically permitted by the authorities. Consequently, in the absence of any legislation mandating further investigation, the pharmaceutical industry have predictably, and to some extent understandably, chosen to avoid the considerable burden of paediatric trials.
In a paper from 1968, the paediatrician Harry Shirkey 8 coined the phrase 'therapeutic orphans' to highlight the extent to which children are neglected-in comparison to adults-when it comes to the development of new medical products and procedures. Over the last few decades, the problem was increasingly recognized in the United States and consecutively in Europe. This principle was then extended first in the United States and later in EU and the term 'orphan drug' was coined for drugs for the treatment of rare diseases (orphan diseases). Because medical research and development of drugs to treat these diseases is financially disadvantageous, companies that do so are rewarded with tax reductions and marketing exclusivity (a 'monopoly'). In 2003, the leading orphan drug by worldwide sales revenue was Amgen's erythropoietin (Epogen), with sales of $2.4 billion. Several initiatives were started, and directives, laws and decrees were implemented to support clinical research in paediatrics ( Table 2 ). In US, all efforts to improve clinical research in children on a voluntary basis failed, subsequently only a moderate improvement in the situation was achieved with patent extension implemented in the socalled 'Modernization Act'. A significant progress was only achieved when a legal obligation was combined with a financial compensation for the conduct of clinical trials in children (Pediatric Research Equity Act). This development was not echoed for another 17 years. Only with the 'Orphan Drug Act' in the year 2000, a modification of the licensing procedure for rare diseases was introduced.
It was soon apparent that the initial EU legislation was crippling academic research and had not addressed the issue of studies in the paediatric population. This was clearly not the intent as demonstrated by the relatively prompt appearance of the draft guidance on specific modalities for non-commercial clinical trials, yet to be finalized, and the EU regulation (EC) no. 1901/2006 'on medicinal products for paediatric use' that was enacted in January 2007.
This regulation is the most serious attempt to facilitate the development and accessibility of medicinal products for the use in children in Europe. It specifies requirements to protect children participating in clinical trials. It is comparable to the US regulation 'Pediatric Research Equity Act' adopted in 2003 that eventually had a significant impact on clinical trials in US over the following years. The draft guidelines somewhat facilitate investigatorinitiated trials (IITs) but many challenges remain.
Good clinical practice in IITs EU Directive 2001/20/EC, subsequently translated by each member state into national law, imposed the same standards of conduct on non-pharmaceutical or so-called IITs previously only required for pharmaceutical, mostly licensing, trials, with disastrous effects. What was initially meant to simplify and streamline administration and raise the quality of clinical trials turned into a major challenge for all clinical investigators. Not only are the new legal responsibilities (sponsorship) a substantial burden but also the costs for administration, data monitoring and safety, etc. exploded. Again paediatrics were often seen as an economically irrelevant, minority burdened with more risks than benefits, suffered most from this new directive that eventually affected the treatment optimization studies efficiently conducted for decades, which had achieved an overall average survival of 75% in paediatric oncology.
How to design a new study? Basic questions. The most important question for a future principle investigator (PI) is whether it is worthwhile to engage in an enormously labour-intensive, time-consuming, expensive and highly speculative adventure like a clinical trial? Especially in paediatric stem cell transplantation, there is no doubt that, due to the paucity of transplanted patients per centre, the answer to even a simple study question will require a multi-centre and almost always international participation, increasing the costs and administrative burden enormously. Therefore, the following questions should be answered beforehand:
Is the study a question of interest for the community, does it have a priority? What kind of a clinical trial should it be? For example, phase I trials are much more difficult to realize than phase III trials, especially in children.
Statistical considerations
* Incidence: what is the incidence of the disease/medical condition? * Sample size: how many patients do I need to treat to achieve a certain level of significance?
Study design: randomized, blinded and placebocontrolled or open label, single arm, cohort or observational studies, etc.? This question is closely related to the level of evidence the study can achieve (see above and Table 1) . What is the time frame? A large sample size, rare diseases, difficult inclusion criteria and poor compliance will not lead to easy recruitment. Studies with the exception of late effect or long-term follow-up trials, which are de facto long-term endeavours, are difficult to realize within a reasonable time frame, unless you achieve good study compliance across multiple centres and/or countries. Regulatory considerations: the paperwork required to submit the protocol for approval is extensive and also can be expensive. Practicability and accessibility: treatment modalities that are related to certain personal skills or capabilities of a local department, rare, complicated or expensive laboratory tests are quite difficult to be standardized and can lead to a study failure. Potential sponsors and independent financial resources must be considered early to avoid undue delays.
Data quality
The cornerstone of every clinical trial is the data quality. In simple terms, data quality can be based on the following 'trinity', that is, stringency, data gathering and storage, and monitoring. A study trying to answer a scientifically/ therapeutically important question with a high recruitment rate but poor data quality will diminish the power of the study or can even invalidate it in the end. First and foremost, the study design should focus on the most important questions to achieve a high compliance of the study in terms of participation and stringency.
In general, clinical research continues to adhere to the paper-based model of data gathering and storage. This percentage is expected to decline steadily over the next few years because of a greater rate of implementation of technology in the data collection and review process. Electronic data capture (EDC) positively impacts on quality, time and cost. 9, 10 Good clinical practice (GCP) requirements that relate to EDC are listed formally under Section 5.5 in the 'Guideline for Good Clinical Practice' (http://www.emea.eu.int/pdfs/human/ich/013595en.pdf).
One of the many benefits of EDC data collection and review is its initial data-entry-tracking capability. This is a decided advantage over the paper-based model as it offers a level of password protection/security in entering data to a CRF, which is not possible in the paper-based model, and also facilitates tracking the progress of data capture.
The third impact on data quality is monitoring. The monitor(s) in accordance with the sponsor's requirements should ensure that the trial is conducted and documented properly. Next to an appropriate study design with an appealing, transparent and safe data-gathering method by EDC, efficient monitoring in compliance with the criteria indicated above is the best warranty for a successful clinical trial, with well-trained monitors being invaluable tools for high data quality. (The entire document on International Conference on Harmonization (ICH) Topic E 6 (R1) Guideline for Good Clinical Practice can be downloaded from the European Medicine Evaluation Agency's (EMEA) website (http://www.emea.eu.int/pdfs/human/ich/013595en.pdf).
Administration
As mentioned earlier, the administrative burdens of controlled clinical trials are enormous and should not be underestimated. They will be highlighted and should serve only as examples.
The first challenge for the new PI is the increased amount of information that must be added to ensure that the protocol addresses all elements of study conduct required by ICH-CGP guidelines. Prior to the EU Directive, the average IIT protocol would be limited to the information required to describe who would be treated, how, why and what data would be collected. Under current legislation, all aspects of study conduct must be detailed in the protocol, including adverse event handling, data management, monitoring, quality assurance, audit, archiving of data, and ethical and regulatory submissions, etc. Protocols are much longer and very time consuming to produce.
Once finalized, the protocol must be registered on the EUdraCT database and assigned its EUdraCT number. This step is followed by the submission to the competent authorities and ethical committees. With the failure of harmonization, general recommendations cannot be made. Some countries streamlined and simplified submissions and some by standardized online procedures, whereas other countries maintained national and even regional particularities that often require native language skills and support from experts in the field.
Another utmost tedious but important step is the contractual affairs between all participants, which may include some or all of the following: the sponsor(s), the PI and its academic institution, the contract research organization, the participating centres, EDC management, if trial medication is involved, eventually pharmacies, and others. It is obvious that this task of international law can only be mastered by an experienced personnel with access to legal advice.
Monitoring manuals, standard operating procedures, quality assurance and control have to be generated and adverse event and serious adverse event management must be installed according to the GCP guidelines (Section I). An independent data-monitoring committee or data-and safety-monitoring board has to be established that assesses at intervals the progress of a clinical trial, the safety data, the critical efficacy end points and recommends to the sponsor whether to continue, modify or stop a trial. This board needs to be equipped with a data-and safetymonitoring board charter and a prospective statistical analysis plan detailing the standard operating procedures, the time intervals of their meetings and the format of their reports among others. The statistical analysis plan is an important tool for the data-and safety-monitoring board to assure rightful conduct of the study.
The infrastructure to support data management independent of the PI is mandatory, to deal with the daily issues concerning randomization, drug distribution, database and query management, liaison with the participating centres and the contract research organization, IRB issues and information on issues concerning adverse event and serious adverse event.
Last but not the least, monitor-training sessions and investigator meetings have to be organized for study presentation. Table 3 summarizes many but not all possible fees and charges that can easily reach one million EU per trial. A major issue that was not considered by the authorities when GCP conformity was required by law for IIT was how to finance these quasi-industrial trials. Neither academic institutions, national grant givers nor the international medical societies are capable of conducting GCP conformation trials on their own without completely exhausting their financial resources.
Financing

Possible solutions for the various problems
Clinical trials are the most important tool to improve the quality of medical conduct and are needed particularly in paediatrics, but the current situation is a major challenge for non-industrial academic trials. The problems are known to the industry and are summarized in the 'trinity of factors': quality, time and costs. 9 There is space for improvement at every level. Starting with the future PI, institutionalized training on the legal and ethical aspects, design, conduct, statistical analysis and management of clinical trials as well as on the awareness for data quality and evidence in medicine is necessary. Academic boards consisting of clinicians, IRB representatives, lawyers, pharmacists, statisticians, nurses and others are in the process of being constituted to assess and guide potential new clinical projects. The legal departments are still mostly overwhelmed with the new regulations and the particularities of international European law must be trained. One solution could be institutional clinical trial offices overseeing and supporting the progress of any proposal.
There are still significant deficits at the national and the European levels. Next to a substantial raise of the budget, a harmonization of international laws and regulations is obligatory. This process was initiated in the 1980s and culminated in the 'International Conference on Harmonization' also including USA and Japan. Nevertheless, there is still space for improvement starting with the registration process that differs substantially on the international and even regional levels.
The various medical societies will have to improve their infrastructure for clinical trials similar to the 'Prospective Clinical Trials Committee (PCTC)' of the EBMT (see below). Clinical trial offices of medical societies can help with administration, know-how, insurance coverage and a certified EDC structure adaptable to various studies.
Monitoring is the major financial burden of any clinical trial. Large industrial contract research organizations have a large administrative overhead and are, therefore, the wrong partners for small IITs. Clinical research in children is becoming a main focus of the EU. This is a reaction to the hesitation of the pharmaceutical industry to conduct proper studies in children. The main drivers of overall return on investment are the size of the pharmaceutical market and the price achievable within the marketplace. The number of children suffering from specific diseases is generally lower than the number of adults and, in terms of research, 'children' cannot be considered a single population so studies may be more complex. The current situation in EU regarding medicines for children is clear evidence that market forces alone are insufficient to stimulate adequate research into and authorization of medicines for children. The last on the list of consequence was the implementation of the EU decree 'on medicinal products for paediatric use' in January 2007, and there are more to come. Under this pressure, the pharmaceutical industry might seek the collaboration with academic institutions conducting research as co-sponsored trials with the advantage of a higher compliance of the participating institutions and therefore better data quality in a shorter period of time and for much less expenses than an industrial trial.
For medical associations also representing children, similar guidelines and regulations on the EU level might become necessary to push the conduct of clinical trials in this sub-population.
Last but not the least, the public must be educated about the benefit of controlled clinical trials in children.
The EBMT model
The EBMT initiated the PCTC to support EBMT-related IITs. The responsibility of the PCTC is to: advise investigators on new protocols; expedite review of protocols; make recommendations to the board on the adoption/ rejection of protocols; review the costing of any proposed study to ensure that sufficient funds are available to run the study as an EBMT-sponsored study; audit of studies to ensure that all EBMT-sponsored studies are run in accordance with ICH-GCP, the EU Directive(s) and any other laws applicable to non-EU countries; participate as members of the Independent Data Monitoring Committees for EBMT protocols; review the reports of the independent data-monitoring committees and ensure timelines are adhered to; liaise with representatives of the pharmaceutical industry to facilitate access to new compounds and funded research opportunities; source grant programmes and submit proposals to consolidate and build the clinical trials support infrastructure.
But trial development does not start at the PCTC level to ensure that minimal amount of time is spent developing a protocol, prior to confirmation of its adoption. With the paediatric perspective in mind, a paediatric subcommittee on clinical trials was proposed. This subcommittee should consist of members of both paediatric working parties, including the Inborn Error Working Party, statisticians, members of the PCTC, possibly ethical advisors and pharmacists. The subcommittee would review applications and proposals for potential new trials after the paediatric community signals its support for the proposed study, supporting in close collaboration with the PCTC, the future PI in the most crucial aspects of study design, administration and study launch.
